A targetable ‘rogue’ neutrophil-subset, [CD11b+DEspR+] immunotype, is associated with severity and mortality in acute respiratory distress syndrome (ARDS) and COVID-19-ARDS

Victoria L. M. Herrera, Allan J. Walkey, Mai Q. Nguyen, Christopher M. Gromisch, Julie Z. Mosaddhegi, Matthew S. Gromisch, Bakr Jundi, Soeren Lukassen, Saskia Carstensen, Ridiane Denis, Anna C. Belkina, Rebecca M. Baron, Mayra Pinilla-Vera, Meike Mueller, W. Taylor Kimberly, Joshua N. Goldstein, Irina Lehmann, Angela Shih, Roland Eils, Bruce D. Levy, Nelson Ruiz‐OpazoScientific 2022 · DOI

TL;DR

Researchers have identified a specific subset of neutrophils, characterized by the CD11b+DEspR+ immunotype, that are strongly associated with the severity and mortality of Acute Respiratory Distress Syndrome (ARDS) and COVID-19-ARDS. These "rogue" neutrophils exhibit delayed apoptosis and contribute to harmful inflammation, but importantly, they can be targeted by a novel antibody, offering a potential therapeutic avenue.

What Problem Does This Paper Address?

Acute Respiratory Distress Syndrome (ARDS) is a life-threatening condition characterized by severe lung inflammation and injury, often leading to multi-organ failure and death. A significant contributor to this secondary tissue damage is the dysregulated activity of neutrophils, immune cells that, when overactive, can cause harm through mechanisms like neutrophil extracellular traps (NETs). While many therapeutic approaches have been explored, there's a critical need for targeted therapies that can specifically shut down these harmful neutrophils without compromising the immune system's ability to fight off infections. This paper addresses this by investigating a specific neutrophil subset that appears to be resistant to normal apoptotic processes, making them a prime suspect for causing persistent inflammation in ARDS and COVID-19-ARDS.

Methods

The study employed a multi-pronged approach:

  • Flow Cytometry (FCM): This was the primary technique used to identify and quantify different neutrophil subsets based on cell surface markers like CD11b and DEspR. They optimized protocols for analyzing patient blood samples.
  • Immunofluorescence (IF) and Immunohistochemistry (IHC): These techniques were used to visualize DEspR+ neutrophils and NETs in lung tissue samples from ARDS and COVID-19-ARDS patients, as well as in blood smears.
  • Western Blotting: Used to confirm the presence and levels of DEspR protein in neutrophils and kidney tissue.
  • Single-cell RNA Sequencing (scRNA-seq): Analyzed gene expression in immune cells from COVID-19 patients to understand the molecular pathways associated with DEspR and its potential role in the disease.
  • Ex Vivo Assays: Patient and Rhesus macaque neutrophils were treated with a humanized anti-DEspR antibody (hu6g8) to assess its effect on neutrophil apoptosis, function, and NET formation.
  • Live-cell Imaging: Used to observe the dynamic interactions of the anti-DEspR antibody with neutrophils and its impact on cell behavior in real-time.

Datasets

  • Normal Human Volunteer (NHV) Neutrophils: Used for initial characterization of DEspR expression and optimization of flow cytometry protocols.
  • ARDS Patient Samples: Blood and post-mortem lung tissue samples from patients with ARDS (pre-COVID-19 pandemic) were used to study the DEspR+ neutrophil subset and its association with disease severity and mortality.
  • COVID-19-ARDS Patient Samples: Blood and lung tissue samples from patients with COVID-19-ARDS were analyzed similarly to ARDS patients, with additional scRNA-seq data from nasopharyngeal and broncho-lavage fluid samples.
  • Rhesus Macaque Neutrophils: Used as a model system for live-cell imaging studies to assess the effects of the anti-DEspR antibody.

Key Insights and Ideas

  • A "Rogue" Neutrophil Subset: The identification of the CD11b+DEspR+ neutrophil subset as a distinct entity with pathogenic potential is a major finding. These neutrophils seem to evade normal programmed cell death.
  • DEspR as a Target: The DEspR receptor itself is highlighted as a key vulnerability. Its presence on these harmful neutrophils, and its role in their survival, makes it an attractive therapeutic target.
  • NET Formation Link: The study strongly links this DEspR+ neutrophil subset to increased intravascular NET formation, a process known to contribute to organ damage.
  • Therapeutic Potential of Anti-DEspR Antibody: The development and ex vivo validation of the hu6g8 antibody, which can induce apoptosis in DEspR+ neutrophils, offers a promising new therapeutic strategy.
  • COVID-19 and ARDS Commonalities: The research underscores shared neutrophil dysregulation mechanisms between ARDS and COVID-19-ARDS, suggesting that therapies targeting this subset could be broadly applicable.

Key Results

  • Increased peripheral CD11b+DEspR+ neutrophil counts were significantly associated with higher severity and mortality in both ARDS and COVID-19-ARDS patients.
  • DEspR+ neutrophils were detected in lung tissue of ARDS and COVID-19-ARDS patients.
  • scRNA-seq data revealed increased expression of DEspR pathway genes in neutrophils from COVID-19 patients, suggesting an active molecular network driving their dysfunction.
  • Unlike DEspR[-] neutrophils, DEspR+CD11b+ neutrophils exhibited delayed apoptosis.
  • The humanized anti-DEspR antibody, hu6g8, effectively blocked this delayed apoptosis in ex vivo assays and induced apoptosis in Rhesus macaque neutrophils.
  • A correlation was found between the number of DEspR+CD11b+ NET-forming neutrophils and clinical measures of ARDS severity and mortality.

Limitations and Future Work

  • Pilot Study Size: The study acknowledges the limitations of its pilot observational nature, with relatively small sample sizes for ARDS (n=19) and COVID-19-ARDS (n=11) patient cohorts.
  • PFA Fixation Impact: For COVID-19-ARDS samples, the use of paraformaldehyde (PFA) for disinfection limited the ability to perform certain plasma biomarker analyses (e.g., ELISA for MPO-DNA complexes).
  • In Vivo Efficacy: While ex vivo studies showed promising results for the hu6g8 antibody, further in vivo studies are needed to confirm its efficacy and safety in animal models and eventually in human clinical trials.
  • On-Target Effects: The authors note the presence of DEspR in human kidney tubular epithelial cells and suggest further investigation into potential on-target effects in the context of acute kidney injury, though they hypothesize that antibody functionality might be altered in the kidney's environment.
  • Broader Cell Involvement: The study primarily focused on neutrophils, and future work could explore the role of DEspR in other immune cells and their interactions in ARDS pathogenesis.

Summary updated

Abstract

Neutrophil-mediated secondary tissue injury underlies acute respiratory distress syndrome (ARDS) and progression to multi-organ-failure (MOF) and death, processes linked to COVID-19-ARDS. This secondary tissue injury arises from dysregulated neutrophils and neutrophil extracellular traps (NETs) intended to kill pathogens, but instead cause cell-injury. Insufficiency of pleiotropic therapeutic approaches delineate the need for inhibitors of dysregulated neutrophil-subset(s) that induce subset-specific apoptosis critical for neutrophil function-shutdown. We hypothesized that neutrophils expressing the pro-survival dual endothelin-1/VEGF-signal peptide receptor, DEspR, are apoptosis-resistant like DEspR+ cancer-cells, hence comprise a consequential pathogenic neutrophil-subset in ARDS and COVID-19-ARDS. Here, we report the significant association of increased peripheral DEspR+CD11b+ neutrophil-counts with severity and mortality in ARDS and COVID-19-ARDS, and intravascular NET-formation, in contrast to DEspR[-] neutrophils. We detect DEspR+ neutrophils and monocytes in lung tissue patients in ARDS and COVID-19-ARDS, and increased neutrophil RNA-levels of DEspR ligands and modulators in COVID-19-ARDS scRNA-seq data-files. Unlike DEspR[-] neutrophils, DEspR+CD11b+ neutrophils exhibit delayed apoptosis, which is blocked by humanized anti-DEspR-IgG4<sup>S228P</sup> antibody, hu6g8, in ex vivo assays. Ex vivo live-cell imaging of Rhesus-derived DEspR+CD11b+ neutrophils showed hu6g8 target-engagement, internalization, and induction of apoptosis. Altogether, data identify DEspR+CD11b+ neutrophils as a targetable 'rogue' neutrophil-subset associated with severity and mortality in ARDS and COVID-19-ARDS.
BibTeX
@inproceedings{herrera2022targetable,
  author = {Victoria L. M. Herrera and Allan J. Walkey and Mai Q. Nguyen and Christopher M. Gromisch and Julie Z. Mosaddhegi and Matthew S. Gromisch and Bakr Jundi and Soeren Lukassen and Saskia Carstensen and Ridiane Denis and Anna C. Belkina and Rebecca M. Baron and Mayra Pinilla-Vera and Meike Mueller and W. Taylor Kimberly and Joshua N. Goldstein and Irina Lehmann and Angela Shih and Roland Eils and Bruce D. Levy and Nelson Ruiz‐Opazo},
  title = {{A targetable ‘rogue’ neutrophil-subset, [CD11b+DEspR+] immunotype, is associated with severity and mortality in acute respiratory distress syndrome (ARDS) and COVID-19-ARDS}},
  booktitle = {Scientific},
  year = {2022},
  doi = {10.1038/s41598-022-09343-1},
}
Figure